Business Context and Reporting Period
This Form 8-K was filed by vTv Therapeutics Inc. on July 6, 2018. The report details a specific corporate event regarding the unregistered sale of equity securities.
Key Financial Metrics
The filing reports a capital raise of $2.5 million. This transaction involved the issuance of 570,776 shares of Class A common stock at a price of $4.38 per share. The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The material change reported is the execution of a purchase agreement with MacAndrews & Forbes Group LLC. The Company exercised its right under a letter agreement dated December 5, 2017, to require the Investor to purchase the specified shares. This transaction increased the Company's cash position by $2.5 million and diluted existing shareholders through the issuance of new shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the disclosure of the equity sale. The transaction was executed pursuant to definitive documentation and a prior letter agreement.
Investor Verification Checklist
- Verify the terms of the letter agreement dated December 5, 2017, referenced as Exhibit 10.18 in the Company's 2018 Form 10-K.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's cash burn rate to understand the runway provided by the $2.5 million infusion.
- Check for any subsequent filings regarding the use of proceeds from this capital raise.